SGMO Sangamo Therapeutics
- 0.544
- +0.029+5.61%
- 0.540
- -0.004-0.70%
Sangamo Therapeutics News
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | ARS: Annual Report to Security Holders
Sangamo Therapeutics | DEF 14A: Definitive information statements
Sangamo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Sangamo Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 424B5: Prospectus
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Sangamo Therapeutics | 10-K: Annual report
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Duraibabu Prathyusha
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dubois-Stringfellow Nathalie
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Willoughby Scott B.
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pooler Amy
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Macrae Sandy
Sangamo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(7.10%)
Sangamo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Biogen Inc.(8.26%),Biogen MA Inc.(8.26%)
Sangamo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.9%)
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pooler Amy
Analysis
Price Target
No Data
